drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous, gene-modified CD19-directed CAR T-cell therapy; patient T cells are lentivirally transduced (3rd-generation vector, FMC63 scFv), rapidly manufactured (~17–20 h), and infused. CD19 engagement activates T cells to proliferate and kill CD19+ B cells.
nci_thesaurus_concept_id
C188238
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-expressing T-lymphocytes UF-KURE19
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) that targets the human tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes UF-KURE19 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a CD19-directed CAR (FMC63 scFv; third-generation). Upon binding CD19 on B cells, CAR signaling activates and expands the T cells, leading to targeted lysis of CD19-positive malignant (and normal) B cells through perforin/granzyme release and cytokine-mediated cytotoxicity.
drug_name
UF-KURE19 CAR-T cells
nct_id_drug_ref
NCT05400109